PD-1/PD-L1和CTLA-4单克隆抗体:胃肠道毒性和治疗

Q4 Immunology and Microbiology 中华微生物学和免疫学杂志 Pub Date : 2019-10-31 DOI:10.3760/CMA.J.ISSN.0254-5101.2019.10.012

Y. Fei, X. Ren, Xianhuo Wang, Huilai Zhang

{"title":"PD-1/PD-L1和CTLA-4单克隆抗体:胃肠道毒性和治疗","authors":"Y. Fei, X. Ren, Xianhuo Wang, Huilai Zhang","doi":"10.3760/CMA.J.ISSN.0254-5101.2019.10.012","DOIUrl":null,"url":null,"abstract":"PD-1/PD-L1 (programmed cell death 1/programmed cell death 1 ligand 1) and CTLA-4 (cytotoxic T lymphocyte antigen 4) are currently approved major immune checkpoints. Immune checkpoint inhibitors against them are novel monoclonal antibodies that perform well in a variety of malignancies such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma and Hodgkin′s lymphoma. However, with the increasing use of immune checkpoint inhibitors, immune-related adverse events cannot be ignored. The incidence of gastrointestinal toxicity is second only to skin toxicity. In this review, we focused on the mechanisms of these immune checkpoint inhibitors and the characteristics of gastrointestinal toxicity induced by them, and also discussed the clinical management strategies. \n \nKey words: \nImmune checkpoint inhibitor; Gastrointestinal toxicity","PeriodicalId":10089,"journal":{"name":"中华微生物学和免疫学杂志","volume":"39 1","pages":"794-799"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"PD-1/PD-L1 and CTLA-4 monoclonal antibodies: gastrointestinal toxicity and treatment\",\"authors\":\"Y. Fei, X. Ren, Xianhuo Wang, Huilai Zhang\",\"doi\":\"10.3760/CMA.J.ISSN.0254-5101.2019.10.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"PD-1/PD-L1 (programmed cell death 1/programmed cell death 1 ligand 1) and CTLA-4 (cytotoxic T lymphocyte antigen 4) are currently approved major immune checkpoints. Immune checkpoint inhibitors against them are novel monoclonal antibodies that perform well in a variety of malignancies such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma and Hodgkin′s lymphoma. However, with the increasing use of immune checkpoint inhibitors, immune-related adverse events cannot be ignored. The incidence of gastrointestinal toxicity is second only to skin toxicity. In this review, we focused on the mechanisms of these immune checkpoint inhibitors and the characteristics of gastrointestinal toxicity induced by them, and also discussed the clinical management strategies. \\n \\nKey words: \\nImmune checkpoint inhibitor; Gastrointestinal toxicity\",\"PeriodicalId\":10089,\"journal\":{\"name\":\"中华微生物学和免疫学杂志\",\"volume\":\"39 1\",\"pages\":\"794-799\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"中华微生物学和免疫学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.0254-5101.2019.10.012\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Immunology and Microbiology\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"中华微生物学和免疫学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.0254-5101.2019.10.012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 0

摘要

PD-1/PD-L1(程序性细胞死亡1/程序性细胞死亡1配体1)和CTLA-4(细胞毒性T淋巴细胞抗原4)是目前被批准的主要免疫检查点。针对它们的免疫检查点抑制剂是一种新型单克隆抗体，在各种恶性肿瘤如黑色素瘤、肾细胞癌、非小细胞肺癌、尿路上皮癌和霍奇金淋巴瘤中表现良好。然而，随着免疫检查点抑制剂使用的增加，免疫相关的不良事件也不容忽视。胃肠道毒性的发生率仅次于皮肤毒性。本文就免疫检查点抑制剂的作用机制、胃肠道毒性的特点进行综述，并讨论其临床处理策略。关键词:免疫检查点抑制剂;胃肠道毒性

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

PD-1/PD-L1 and CTLA-4 monoclonal antibodies: gastrointestinal toxicity and treatment

PD-1/PD-L1 (programmed cell death 1/programmed cell death 1 ligand 1) and CTLA-4 (cytotoxic T lymphocyte antigen 4) are currently approved major immune checkpoints. Immune checkpoint inhibitors against them are novel monoclonal antibodies that perform well in a variety of malignancies such as melanoma, renal cell carcinoma, non-small-cell lung cancer, urothelial carcinoma and Hodgkin′s lymphoma. However, with the increasing use of immune checkpoint inhibitors, immune-related adverse events cannot be ignored. The incidence of gastrointestinal toxicity is second only to skin toxicity. In this review, we focused on the mechanisms of these immune checkpoint inhibitors and the characteristics of gastrointestinal toxicity induced by them, and also discussed the clinical management strategies. Key words: Immune checkpoint inhibitor; Gastrointestinal toxicity

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

中华微生物学和免疫学杂志 Immunology and Microbiology-Virology

CiteScore

0.50

自引率

0.00%

发文量

6906

期刊介绍： Chinese Journal of Microbiology and Immunology established in 1981. It is one of the series of journal sponsored by Chinese Medical Association. The aim of this journal is to spread and exchange the scientific achievements and practical experience in order to promote the development of medical microbiology and immunology. Its main contents comprise academic thesis, brief reports, reviews, summaries, news of meetings, book reviews and trends of home and abroad in this field. The distinguishing feature of the journal is to give the priority to the reports on the research of basic theory, and take account of the reports on clinical and practical skills.